Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Dolutegravir Filed for Approval in Europe, the US and Canada: Shionogi
December 20, 2012
- Sanofi’s JAK2 Inhibitor Improves Symptoms in Patients with MF in PII Trial
December 20, 2012
- Carsten Brunn to Take Over as President of Bayer Yakuhin in March 2013
December 20, 2012
- Eisai Transfers US Rights for Brain Tumor Treatment to Arbor Pharm
December 19, 2012
- Crestor Patent Upheld by US Court of Appeals for the Federal Circuit: Shionogi
December 19, 2012
- Takeda to Sell URL Pharma’s Generic Drug Business to Caraco
December 19, 2012
- Elmed Eisai, Kobayashi Kako Allegra Generics Not Launched on December 14
December 18, 2012
- Takeda Faces Generic Entry for Candesartan in US
December 18, 2012
- Eisai to Form Alliance with University College London for Drug Discovery Research
December 18, 2012
- Chugai to Adopt IFRS from FY2013
December 18, 2012
- Takeda Launches Phone Service to Support Patients’ Drug Administration
December 17, 2012
- Pfizer Specialty Care Chief Hopeful about Japan Vaccine Market, Novel RA Treatment
December 17, 2012
- AstraZeneca’s Novel RA Drug Fostamatinib Fails to Demonstrate Non-Inferiority to Humira in PIIb Study
December 17, 2012
- Eli Lilly to Conduct Additional Trial of Novel AD Treatment Solanezumab
December 17, 2012
- Eli Lilly to Discontinue One of Three PIII Rheumatoid Arthritis Registration Studies of Tabalumab
December 17, 2012
- Janssen Research & Development Submits NDA for Canagliflozin/Metformin Fixed-Dose Combination in the US
December 17, 2012
- Eisai Concludes Strategic Manufacturing Alliance with Biogen Idec for Contract Manufacturing at Eisai Inc.’s US Plant
December 17, 2012
- Elmed Eisai, Kobayashi Kako Get Their Allegra Generics Listed
December 14, 2012
- Calls by MRs from Pfizer Japan Left Best Impression at Insurance Pharmacies in October: Nextit Research
December 14, 2012
- ADCETRIS Shows Tolerability in Untreated HL Patients: Takeda
December 14, 2012
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…